Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sphincter-saving surgery for ultra-low rectal carcinoma initially indicated for abdominoperineal resection: Is it safe on a long-term follow-up?
Rouanet P, Rivoire M, Gourgou S, Lelong B, Rullier E, Jafari M, Mineur L, Pocard M, Faucheron JL, Dravet F, Pezet D, Fabre JM, Bresler L, Balosso J, Taoum C, Lemanski C. Rouanet P, et al. Among authors: dravet f. J Surg Oncol. 2021 Jan;123(1):299-310. doi: 10.1002/jso.26249. Epub 2020 Oct 24. J Surg Oncol. 2021. PMID: 33098678 Clinical Trial.
Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial.
Rouanet P, Rivoire M, Gourgou S, Lelong B, Rullier E, Jafari M, Mineur L, Pocard M, Faucheron JL, Dravet F, Pezet D, Fabre JM, Bresler L, Balosso J, Lemanski C. Rouanet P, et al. Among authors: dravet f. Br J Surg. 2021 Jan 27;108(1):10-13. doi: 10.1093/bjs/znaa010. Br J Surg. 2021. PMID: 33640922 Clinical Trial. No abstract available.
Cost comparison of axillary sentinel lymph node detection and axillary lymphadenectomy in early breast cancer. A national study based on a prospective multi-institutional series of 985 patients 'on behalf of the Group of Surgeons from the French Unicancer Federation'.
Classe JM, Baffert S, Sigal-Zafrani B, Fall M, Rousseau C, Alran S, Rouanet P, Belichard C, Mignotte H, Ferron G, Marchal F, Giard S, Tunon de Lara C, Le Bouedec G, Cuisenier J, Werner R, Raoust I, Rodier JF, Laki F, Colombo PE, Lasry S, Faure C, Charitansky H, Olivier JB, Chauvet MP, Bussières E, Gimbergues P, Flipo B, Houvenaeghel G, Dravet F, Livartowski A. Classe JM, et al. Among authors: dravet f. Ann Oncol. 2012 May;23(5):1170-1177. doi: 10.1093/annonc/mdr355. Epub 2011 Sep 6. Ann Oncol. 2012. PMID: 21896543 Free PMC article.
Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T. Rouanet P, et al. Among authors: dravet f. J Clin Oncol. 2005 May 1;23(13):2980-7. doi: 10.1200/JCO.2005.06.064. J Clin Oncol. 2005. PMID: 15860853 Clinical Trial.
67 results